Published in J Biol Chem on October 31, 2012
Stargazin promotes closure of the AMPA receptor ligand-binding domain. J Gen Physiol (2014) 1.10
Structure of an agonist-bound ionotropic glutamate receptor. Science (2014) 1.08
Asynchronous movements prior to pore opening in NMDA receptors. J Neurosci (2013) 1.01
Structure and gating of tetrameric glutamate receptors. J Physiol (2013) 0.94
Analyzing single-molecule time series via nonparametric Bayesian inference. Biophys J (2015) 0.93
Amino-terminal domain tetramer organization and structural effects of zinc binding in the N-methyl-D-aspartate (NMDA) receptor. J Biol Chem (2013) 0.92
Structural dynamics of the glycine-binding domain of the N-methyl-D-aspartate receptor. J Biol Chem (2014) 0.88
Reduced curvature of ligand-binding domain free-energy surface underlies partial agonism at NMDA receptors. Structure (2014) 0.86
Conformational transitions in the glycine-bound GluN1 NMDA receptor LBD via single-molecule FRET. Biophys J (2015) 0.80
Error-based extraction of states and energy landscapes from experimental single-molecule time-series. Sci Rep (2015) 0.79
Stargazin Modulation of AMPA Receptors. Cell Rep (2016) 0.78
Mechanism-Based Mathematical Model for Gating of Ionotropic Glutamate Receptors. J Phys Chem B (2015) 0.78
Conformational Selection and Submillisecond Dynamics of the Ligand-binding Domain of the N-Methyl-d-aspartate Receptor. J Biol Chem (2016) 0.77
Structural rearrangement of the intracellular domains during AMPA receptor activation. Proc Natl Acad Sci U S A (2016) 0.77
Role of the Ion Channel Extracellular Collar in AMPA Receptor Gating. Sci Rep (2017) 0.75
The structure-energy landscape of NMDA receptor gating. Nat Chem Biol (2017) 0.75
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol (2007) 6.91
X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature (2009) 6.81
Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron (2000) 6.22
Molecular diversity of glutamate receptors and implications for brain function. Science (1992) 4.90
Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science (1999) 4.56
Structural basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci (2003) 4.55
Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature (1998) 4.14
The structure and function of glutamate receptor ion channels. Nat Rev Neurosci (2002) 2.35
Evolution of glutamate interactions during binding to a glutamate receptor. Nat Chem Biol (2005) 1.84
Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes. Proc Natl Acad Sci U S A (2003) 1.81
Structural and single-channel results indicate that the rates of ligand binding domain closing and opening directly impact AMPA receptor gating. J Neurosci (2008) 1.75
Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct (1994) 1.71
AMPA receptor binding cleft mutations that alter affinity, efficacy, and recovery from desensitization. J Neurosci (2005) 1.70
Structure and function of AMPA receptors. J Physiol (2003) 1.64
Structural landscape of isolated agonist-binding domains from single AMPA receptors. Nat Chem Biol (2011) 1.49
Structural mobility of the extracellular ligand-binding core of an ionotropic glutamate receptor. Analysis of NMR relaxation dynamics. Biochemistry (2002) 1.46
Allosteric mechanism in AMPA receptors: a FRET-based investigation of conformational changes. Proc Natl Acad Sci U S A (2006) 1.46
Dynamics of the S1S2 glutamate binding domain of GluR2 measured using 19F NMR spectroscopy. J Biol Chem (2007) 1.41
Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med (Berl) (2004) 1.40
Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets (2009) 1.30
Mechanism of partial agonism at the GluR2 AMPA receptor: Measurements of lobe orientation in solution. Biochemistry (2008) 1.26
Glutamate receptor channels: novel properties and new clones. Trends Pharmacol Sci (1992) 1.23
AMPA receptor trafficking and learning. Eur J Neurosci (2010) 1.21
Conformational changes in the ligand-binding domain of a functional ionotropic glutamate receptor. J Biol Chem (2005) 1.21
Structure of the S1S2 glutamate binding domain of GLuR3. Proteins (2009) 1.20
Emerging structural explanations of ionotropic glutamate receptor function. FASEB J (2004) 1.19
NMR spectroscopy of the ligand-binding core of ionotropic glutamate receptor 2 bound to 5-substituted willardiine partial agonists. J Mol Biol (2008) 1.15
Ligand--protein interactions in the glutamate receptor. Biochemistry (2000) 1.13
LRET investigations of conformational changes in the ligand binding domain of a functional AMPA receptor. Biochemistry (2008) 1.13
Microsecond-to-millisecond conformational dynamics demarcate the GluR2 glutamate receptor bound to agonists glutamate, quisqualate, and AMPA. Biochemistry (2005) 1.13
Mechanisms of antagonism of the GluR2 AMPA receptor: structure and dynamics of the complex of two willardiine antagonists with the glutamate binding domain. Biochemistry (2009) 1.12
Mechanisms of modal activation of GluA3 receptors. Mol Pharmacol (2011) 1.11
Role of dimer interface in activation and desensitization in AMPA receptors. Proc Natl Acad Sci U S A (2010) 1.10
Denoising single-molecule FRET trajectories with wavelets and Bayesian inference. Biophys J (2010) 1.09
AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets (2007) 1.08
Structure of glutamate receptors. Curr Drug Targets (2007) 1.07
Enhanced efficacy without further cleft closure: reevaluating twist as a source of agonist efficacy in AMPA receptors. J Neurosci (2010) 1.03
Stereochemistry of glutamate receptor agonist efficacy: engineering a dual-specificity AMPA/kainate receptor. Biochemistry (2004) 1.02
Mechanism of AMPA receptor activation by partial agonists: disulfide trapping of closed lobe conformations. J Biol Chem (2011) 0.99
Chemical interplay in the mechanism of partial agonist activation in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Biochemistry (2007) 0.98
Spectroscopic and kinetic methods for ligand-protein interactions of glutamate receptor. Methods Enzymol (2004) 0.96
Hydrophobic side chain dynamics of a glutamate receptor ligand binding domain. J Biol Chem (2010) 0.92
Dynamics of an anti-VEGF DNA aptamer: a single-molecule study. Biochem Biophys Res Commun (2008) 0.92
Improved resolution of complex single-molecule FRET systems via wavelet shrinkage. J Phys Chem B (2011) 0.91
Single-molecule fluorescence resonance energy transfer in nanopipets: improving distance resolution and concentration range. Anal Chem (2007) 0.88
Glutamate receptors as seen by light: spectroscopic studies of structure-function relationships. Braz J Med Biol Res (2007) 0.87
Cations but not anions regulate the responsiveness of kainate receptors. J Neurosci (2011) 0.87
Fourier transform infrared spectroscopic characterization of a photolabile precursor of glutamate. FEBS Lett (2000) 0.84
Unraveling electronic energy transfer in single conjugated polyelectrolytes encapsulated in lipid vesicles. Proc Natl Acad Sci U S A (2010) 0.83
Stereochemistry of quinoxaline antagonist binding to a glutamate receptor investigated by Fourier transform infrared spectroscopy. J Biol Chem (2001) 0.83
Modulation of AMPA receptor function in relation to glutamatergic abnormalities in Alzheimer's disease. Biomed Pharmacother (1994) 0.79
Ecology: The Convention on Biological Diversity's 2010 target. Science (2005) 5.22
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Southern Ocean iron enrichment experiment: carbon cycling in high- and low-Si waters. Science (2004) 2.43
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet (2006) 1.91
Evolution of glutamate interactions during binding to a glutamate receptor. Nat Chem Biol (2005) 1.84
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS (2003) 1.76
Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing (2005) 1.57
Processing interaural cues in sound segregation by young and middle-aged brains. J Am Acad Audiol (2009) 1.54
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis (2005) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Structural landscape of isolated agonist-binding domains from single AMPA receptors. Nat Chem Biol (2011) 1.49
Allosteric mechanism in AMPA receptors: a FRET-based investigation of conformational changes. Proc Natl Acad Sci U S A (2006) 1.46
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
Insights on the role of nucleic acid/protein interactions in chaperoned nucleic acid rearrangements of HIV-1 reverse transcription. Proc Natl Acad Sci U S A (2007) 1.37
Multidisciplinary approach to the challenge of hemostasis. Anesth Analg (2009) 1.37
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS (2004) 1.28
A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res (2012) 1.28
Single-molecule FRET studies of important intermediates in the nucleocapsid-protein-chaperoned minus-strand transfer step in HIV-1 reverse transcription. Biophys J (2005) 1.26
Conformational changes in the ligand-binding domain of a functional ionotropic glutamate receptor. J Biol Chem (2005) 1.21
The quality of drinking water from private water supplies in Aberdeenshire, UK. Water Res (2003) 1.15
Subunit arrangement in N-methyl-D-aspartate (NMDA) receptors. J Biol Chem (2010) 1.15
Evidence for non-two-state kinetics in the nucleocapsid protein chaperoned opening of DNA hairpins. J Phys Chem B (2006) 1.14
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS (2002) 1.14
LRET investigations of conformational changes in the ligand binding domain of a functional AMPA receptor. Biochemistry (2008) 1.13
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol (2006) 1.12
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J Infect Dis (2002) 1.10
Role of dimer interface in activation and desensitization in AMPA receptors. Proc Natl Acad Sci U S A (2010) 1.10
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials (2002) 1.09
Denoising single-molecule FRET trajectories with wavelets and Bayesian inference. Biophys J (2010) 1.09
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08
Assessment of stream ecosystem function and sensitivity in the Bighorn National Forest, Wyoming. Environ Manage (2007) 1.07
Conformational changes at the agonist binding domain of the N-methyl-D-aspartic acid receptor. J Biol Chem (2011) 1.07
Role of the chemical interactions of the agonist in controlling alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation. Biochemistry (2007) 1.04
Harvesting the high-hanging fruit: the structure of the YdeN gene product from Bacillus subtilis at 1.8 angstroms resolution. Acta Crystallogr D Biol Crystallogr (2004) 1.04
Chemistry and conformation of the ligand-binding domain of GluR2 subtype of glutamate receptors. J Biol Chem (2004) 1.04
Establishing a context for river rehabilitation, North Fork Gunnison River, Colorado. Environ Manage (2005) 1.03
Stereochemistry of glutamate receptor agonist efficacy: engineering a dual-specificity AMPA/kainate receptor. Biochemistry (2004) 1.02
A vibrational spectroscopic investigation of interactions of agonists with GluR0, a prokaryotic glutamate receptor. Biochemistry (2002) 1.01
Probing nucleation, reverse annealing, and chaperone function along the reaction path of HIV-1 single-strand transfer. Proc Natl Acad Sci U S A (2007) 1.00
Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. J Immunol (2002) 0.99
Chemical interplay in the mechanism of partial agonist activation in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Biochemistry (2007) 0.98
Na+/Cl- dipole couples agonist binding to kainate receptor activation. J Neurosci (2007) 0.98
In situ measurement of bovine serum albumin interaction with gold nanospheres. Langmuir (2012) 0.98
Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine. Biochim Biophys Acta (2012) 0.97
Resonance Raman and infrared spectroscopic studies of high-output forms of human soluble guanylyl cyclase. J Am Chem Soc (2005) 0.97
Structure and function of Bacillus subtilis YphP, a prokaryotic disulfide isomerase with a CXC catalytic motif . Biochemistry (2009) 0.97
Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 0.96
In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine (2009) 0.95
Adsorption of a Protein Monolayer via Hydrophobic Interactions Prevents Nanoparticle Aggregation under Harsh Environmental Conditions. ACS Sustain Chem Eng (2013) 0.93
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (2003) 0.93
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother (2003) 0.93
Fluorescence correlation spectroscopy: criteria for analysis in complex systems. Anal Chem (2009) 0.93
Dynamics of an anti-VEGF DNA aptamer: a single-molecule study. Biochem Biophys Res Commun (2008) 0.92
Amino-terminal domain tetramer organization and structural effects of zinc binding in the N-methyl-D-aspartate (NMDA) receptor. J Biol Chem (2013) 0.92
Is the isolated ligand binding domain a good model of the domain in the native receptor? J Biol Chem (2003) 0.91
An unusual case of peritonitis in an intravenous drug user. Gastroenterology (2011) 0.91
Improved resolution of complex single-molecule FRET systems via wavelet shrinkage. J Phys Chem B (2011) 0.91
Does physical activity in adolescence have site-specific and sex-specific benefits on young adult bone size, content, and estimated strength? J Bone Miner Res (2014) 0.89
Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet (2004) 0.89
Modification of the QuantiFERON-TB Gold (In-Tube) assay for the diagnosis of Mycobacterium bovis infection in African buffaloes (Syncerus caffer). Vet Immunol Immunopathol (2011) 0.88
Influence of vascular porosity on fluid flow and nutrient transport in loaded cortical bone. J Biomech (2008) 0.88
Strengthening international cooperation for health and biodiversity. Ecohealth (2012) 0.87
A national framework for disaster health education in Australia. Prehosp Disaster Med (2010) 0.87
Single ion diffusive transport within a Poly(styrene sulfonate) polymer brush matrix probed by fluorescence correlation spectroscopy. J Phys Chem B (2008) 0.86
Proton-mediated conformational changes in an acid-sensing ion channel. J Biol Chem (2013) 0.86
Unified superresolution experiments and stochastic theory provide mechanistic insight into protein ion-exchange adsorptive separations. Proc Natl Acad Sci U S A (2014) 0.86
Single molecule spectroscopy reveals heterogeneous transport mechanisms for molecular ions in a polyelectrolyte polymer brush. J Phys Chem B (2009) 0.86
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr (2013) 0.85
Single-particle spectroscopy reveals heterogeneity in electrochemical tuning of the localized surface plasmon. J Phys Chem B (2014) 0.85
Joint statement on mechanical circulatory support in children: a consensus review from the Pediatric Cardiac Intensive Care Society and Extracorporeal Life Support Organization. Pediatr Crit Care Med (2013) 0.84
Super-resolution mbPAINT for optical localization of single-stranded DNA. ACS Appl Mater Interfaces (2013) 0.84
Improved compressed sensing-based algorithm for sparse-view CT image reconstruction. Comput Math Methods Med (2013) 0.84
Permeability of anti-fouling PEGylated surfaces probed by fluorescence correlation spectroscopy. Colloids Surf B Biointerfaces (2011) 0.84
Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models. J Virol (2005) 0.84
Structural basis of the Ca2+ inhibitory mechanism of Drosophila Na+/Ca2+ exchanger CALX and its modification by alternative splicing. Structure (2011) 0.84
IgE binding conformational epitopes of Asp f 3, a major allergen of Aspergillus fumigatus. Clin Immunol (2002) 0.84
Dye diffusion at surfaces: charge matters. Langmuir (2010) 0.84
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother (2015) 0.83
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses (2007) 0.83
Overexpression and functional characterization of the extracellular domain of the human alpha1 glycine receptor. Biochemistry (2008) 0.83
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther (2005) 0.82
Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr (2005) 0.82
Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing. J Acquir Immune Defic Syndr (2003) 0.82
Photobleaching lifetimes of cyanine fluorophores used for single-molecule Förster resonance energy transfer in the presence of various photoprotection systems. Chembiochem (2013) 0.82
Variability in time delay between two models of pulse oximeters for deriving the photoplethysmographic signals. Physiol Meas (2005) 0.82